Genentech: Maureen Beresini | Principal Scientific Manager II, Biochemical & Cellular Pharmacology

Scientists / Our Scientists

"After many years at Genentech, I am still faced with a wealth of new opportunities for learning and collaboration."

Years at Genentech

Publications at Genentech

Awards & Honors

I joined Genentech in 1992 because of its reputation for outstanding science. When I arrived, I was most impressed by the strong collaborative relationships that quickly developed among my colleagues. I feel fortunate that my position has allowed me to connect my past experiences in protein chemistry as a graduate student, cell biology as a postdoctoral fellow, and assay development gained in industry. My many years at Genentech have continually provided me with opportunities to learn and grow scientifically while contributing to the discovery of therapeutics. It has been extremely rewarding to be a part of the growth and development of the small molecule organization from one that makes selective molecules to one that makes drugs that help patients. My recent work in large molecule discovery has allowed me to appreciate the role of process optimization in advancing therapeutic targets.

Featured Publication

Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells.

ACS Med Chem Lett. 2016 Jan 6;7(3):223-8.

Koehler MF, Bergeron P, Blackwood EM, Bowman K, Clark KR, Firestein R, Kiefer JR, Maskos K, McCleland ML, Orren L, Salphati L, Schmidt S, Schneider EV, Wu J, Beresini MH.

View Abstract

My group develops and provides biochemical and cellular assays to promote the discovery of small molecule therapeutics. We use these assays for high-throughput screening, compound profiling, and establishing structure-activity relationships. We have also established state-of-the-art, high-throughput automated systems for managing compounds and conducting assays. We explore and integrate new technologies for assays and automation to improve data quality, increase information content, and streamline processes. We collaborate both internally and externally to build informatics capabilities that facilitate process management and data analysis.

Most recently, I have begun working with our large molecule automation group. I value the opportunity to learn about the intricacies of antibody therapeutics while building on my interests in streamlining and strengthening our drug discovery efforts through automation and information management coupled with rigorous science.

High-Throughput Kinetic Characterization of Irreversible Covalent Inhibitors of KRASG12C by Intact Protein MS and Targeted MRM

Analytical Chemistry, ISSN: 15206882 00032700

Ke Sherry Li; John Quinn; Matthew J. Saabye; Jesus F. Salcido Guerrero; Jim Nonomiya; Qihui Lian; Wilson Phung; Yevgeniy Izrayelit; Benjamin T. Walters; Amy Gustafson; Nicholas F. Endres; Beresini; Melinda M. Mulvihill

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Maureen Beresini

Principal Scientific Manager II, Biochemical & Cellular Pharmacology

Featured Publication

Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells.